Journal of Chemotherapy最新文献

Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance - a review. 长链非编码RNA cas2在肿瘤化疗耐药中的新作用综述

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-04 DOI: 10.1080/1120009X.2026.2739728

Lingyun Zhou, Jintao He, Wenbing Huang, Zhengliang Li, Min Yu, Jiangyan Li, Wenzhong Yang, Wei Xiong

引用次数: 0

Antiviral drug resistance in cytomegalovirus complicating hematopoietic stem cell transplantation: prevalence, genotypic analysis and novel UL97/UL54 variants. 巨细胞病毒并发造血干细胞移植的抗病毒耐药性：患病率、基因型分析和新的UL97/UL54变异

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2026-03-15 DOI: 10.1080/1120009X.2026.2643053

Şerife Çevik, Selma Gökahmetoğlu, Ömür Mustafa Parkan, Leylagül Kaynar, Musa Karakükçü, Mariam Kabirun

{"title":"Antiviral drug resistance in cytomegalovirus complicating hematopoietic stem cell transplantation: prevalence, genotypic analysis and novel UL97/UL54 variants.","authors":"Şerife Çevik, Selma Gökahmetoğlu, Ömür Mustafa Parkan, Leylagül Kaynar, Musa Karakükçü, Mariam Kabirun","doi":"10.1080/1120009X.2026.2643053","DOIUrl":"10.1080/1120009X.2026.2643053","url":null,"abstract":"This study investigated antiviral resistance by sequencing UL97 and UL54 in cytomegalovirus (CMV) strains from haematology and hematopoietic stem cell transplant (HSCT) patients. Fifty-one samples from 48 patients (21 paediatric and 27 adult) with CMV DNA ≥1000 IU/mL and persistent viremia despite therapy were analysed. Resistance-associated mutations were identified in 6/48 patients (12.5%), all HSCT recipients - three paediatric and three adults. Detected mutations included UL97 (A591V, E596G and C603W), combined UL97 (M460I and C592G) and UL54 (F412L) mutations, and a UL54 (L957F) mutation. Additionally, 28 patients harboured 11 previously reported variants not associated with resistance. Novel UL97 (n = 18) and UL54 (n = 20) variants were also identified. In conclusion, prevalence of CMV antiviral resistance was 14.2% in CMV-infected HSCT recipients, slightly higher in paediatric patients. Detection of known and novel UL97/UL54 mutations highlights the importance of monitoring and the need for studies to assess the clinical impact of novel variants.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"527-535"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating eravacycline dosing regimens in the treatment of SSTIs caused by carbapenem-resistant Enterobacteriaceae in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. 评价依瓦环素给药方案治疗成人碳青霉烯耐药肠杆菌科引起的SSTIs：使用蒙特卡洛模拟的药代动力学/药效学分析

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2026-05-19 DOI: 10.1080/1120009X.2026.2675083

Xiang-Jun Yang, Xiao-Chen Wei, Hai-Rong Lyu, Xia Xiao

{"title":"Evaluating eravacycline dosing regimens in the treatment of SSTIs caused by carbapenem-resistant Enterobacteriaceae in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.","authors":"Xiang-Jun Yang, Xiao-Chen Wei, Hai-Rong Lyu, Xia Xiao","doi":"10.1080/1120009X.2026.2675083","DOIUrl":"10.1080/1120009X.2026.2675083","url":null,"abstract":"This study aimed to assess the efficacy of different eravacycline regimens for adult skin and soft-tissue infections (SSTIs) caused by carbapenem-resistant Enterobacteriaceae (CRE). Monte Carlo simulations were performed using pharmacokinetic and pharmacodynamic data to calculate probabilities of target attainment (PTA) and cumulative fractions of response (CFR) according to 24-h free drug area under the concentration curve/minimum inhibitory concentration (MIC) targets. PTA results revealed that the standard 1 mg/kg intravenous q12h regimen exerted bacteriostatic/bactericidal efficacy against Enterobacteriaceae with MIC ≤ 0.5 μg/mL. All simulated regimens achieved CFR values exceeding 90% against Escherichia coli and carbapenem-resistant Escherichia coli. For Enterobacter cloacae complex and Klebsiella pneumoniae, doses of at least 1.5 and 2.5 mg/kg twice daily were required to meet therapeutic targets, respectively. However, few regimens yielded satisfactory efficacy against carbapenem-resistant Enterobacter cloacae complex and Klebsiella pneumoniae. These pharmacokinetic/pharmacodynamic simulations rationalized and optimized eravacycline dosing strategies for CRE-related SSTIs in adult patients.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"536-542"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting. 艾力布林在转移性乳腺癌的现实世界-在印度设置前进的道路。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-08-07 DOI: 10.1080/1120009X.2025.2543127

Dinesh Chandra Doval, Rupal Tripathi, Shweta Jain, Pankaj Goyal, Chaturbhuj Agrawal, Sumit Goyal, Vineet Talwar, Ullas Batra, Rajeev Kumar, Ajay Kumar Dewan

{"title":"Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting.","authors":"Dinesh Chandra Doval, Rupal Tripathi, Shweta Jain, Pankaj Goyal, Chaturbhuj Agrawal, Sumit Goyal, Vineet Talwar, Ullas Batra, Rajeev Kumar, Ajay Kumar Dewan","doi":"10.1080/1120009X.2025.2543127","DOIUrl":"10.1080/1120009X.2025.2543127","url":null,"abstract":"In a real-world setting, this study evaluated clinical parameters and outcomes with the administration of eribulin in heavily pre-treated Indian metastatic breast cancer (MBC) patients using electronic medical records. Among 145 patients, 46.2% were oestrogen/progesterone receptor-positive, 15.9% had HER2-overexpression, and 46.2% had triple-negative breast cancer (TNBC). Eribulin was administered as a 2nd, 3rd, 4th, and ≥5th line chemotherapy in 11.7%, 18.6%, 30.3%, and 39.3% patients, respectively. Grade ≥3 neutropenia occurred in 26.2% of patients. After six cycles, 1.8% had complete response, 17.5% partial response, 17.5% stable disease, and 57.9% experienced disease progression. The overall response rate was 7.6%. Median progression-free survival and overall survival were 3.9 and 11.6 months, respectively. Overall, the study shows low response rate with manageable toxicity. The findings highlight the need for further focused studies comparing eribulin with existing chemotherapies, especially in the Indian patients with disease heterogeneity and unique genetic makeup.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"563-571"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives. 靶向白血病干细胞：通过tivantinib （ARQ197）和asciminib （ABL001）增强根除与分子对接引导的治疗衍生物筛选

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-07-25 DOI: 10.1080/1120009X.2025.2532948

İlknur Karatekin Arik, Nurcan Gümüş, İlayda Alcitepe, Cumhur Gündüz, Belgin Sever, Halil İbrahim Ciftci, Güray Saydam, Burçin Tezcanli Kaymaz

{"title":"Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives.","authors":"İlknur Karatekin Arik, Nurcan Gümüş, İlayda Alcitepe, Cumhur Gündüz, Belgin Sever, Halil İbrahim Ciftci, Güray Saydam, Burçin Tezcanli Kaymaz","doi":"10.1080/1120009X.2025.2532948","DOIUrl":"10.1080/1120009X.2025.2532948","url":null,"abstract":"This study is the first to investigate the therapeutic potential of a mono/combination treatment with the selective phase III BCR::ABL1 tyrosine kinase inhibitor (TKI) asciminib (ABL001) and the c-MET inhibitor tivantinib (ARQ197) in hematopoietic stem cells (HSCs) and leukaemia stem cells (LSCs) in terms of cytotoxicity, apoptosis, target gene expression profiles, and bioinformatics in vitro. In silico studies were also performed for various tivantinib and asciminib derivatives. Asciminib and tivantinib exhibited significant antileukaemic effects, with tivantinib showing the strongest apoptotic impact in LSCs and asciminib in HSCs. Although their combination exhibited an additive effect on LSCs, enabling dose reduction and potentially minimizing side effects; the treatment succeeded in promoting apoptosis as effectively as tivatinib monotherapy. Gene expression analysis showed increased pro-apoptotic and tumour suppressor markers, whereas decreased oncogenes' expressions following mono/combined treatment in LSCs. Molecular docking showed that a new analogue of tivantinib (compound-1) and CHEMBL5274046 are promising c-MET and ABL1 inhibitors, respectively. The findings highlight the antileukaemic potential of initially tivantinib and asciminib in LSCs. Despite an additive effect, combination therapy allowed dose reduction, giving rise to a potential decrease in side effects. Targeting c-MET, alone or in combination with BCR::ABL1 inhibition, presents a compelling strategy for eradicating LSCs, which underpin resistance and relapse in CML therapy - thus marking a crucial advancement in the pursuit of more effective treatment paradigms. In silico studies indicated that various tivantinib and asciminib analogues could also have potential therapeutic effects as c-MET and ABL1 inhibitors for future anti-leukaemia research.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"543-562"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges. 单侧面神经麻痹后延长每周紫杉醇治疗：一个罕见的病例颅神经毒性与诊断挑战。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-07-28 DOI: 10.1080/1120009X.2025.2538945

Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan

{"title":"Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges.","authors":"Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan","doi":"10.1080/1120009X.2025.2538945","DOIUrl":"10.1080/1120009X.2025.2538945","url":null,"abstract":"Background: Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer. While peripheral neuropathy is a well-recognized dose-limiting toxicity of paclitaxel, cranial nerve involvement remains exceptionally rare. We report a case of unilateral facial nerve palsy in a breast cancer patient receiving standard-dose paclitaxel therapy, highlighting the diagnostic challenges in distinguishing drug-induced neurotoxicity from other aetiologies.Case report: A 43-year-old woman with metastatic breast cancer developed left facial nerve paralysis after 12 months of weekly paclitaxel treatment (80 mg/m2). Contrast-enhanced cranial Magnetic Resonance Imaging (MRI) demonstrated bilateral cranial nerve VII enhancement, creating diagnostic uncertainty between leptomeningeal metastasis, paclitaxel-induced neuritis, and idiopathic Bell's palsy. Paclitaxel was discontinued, and corticosteroid therapy was initiated. Clinical and radiological improvement at follow-up strongly supported a drug-related aetiology.Conclusion: This case illustrates the diagnostic complexity of facial nerve palsy in cancer patients receiving neurotoxic chemotherapy. The overlapping clinical and radiological features between drug-induced cranial neurotoxicity, leptomeningeal disease, and idiopathic causes present significant diagnostic challenges. Clinicians should maintain a high degree of suspicion for rare chemotherapy-related cranial neuropathies while pursuing comprehensive differential diagnosis, including infectious aetiologies and metastatic disease.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"598-602"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer. abemaciclib联合阿比特龙治疗转移性去势抵抗性前列腺癌的1期临床研究

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-09-09 DOI: 10.1080/1120009X.2025.2551397

Nobuaki Matsubara, Koji Dozono, Karim Nacerddine, Kaijiro Maeda

引用次数: 0

Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel. 白蛋白结合紫杉醇致急性重型至超重型周围神经病变的影响因素。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-08-19 DOI: 10.1080/1120009X.2025.2547144

Yi Huang, Lijuan Feng, Jing Hu, Fan Zeng

{"title":"Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel.","authors":"Yi Huang, Lijuan Feng, Jing Hu, Fan Zeng","doi":"10.1080/1120009X.2025.2547144","DOIUrl":"10.1080/1120009X.2025.2547144","url":null,"abstract":"Paclitaxel is the primary chemotherapy agents for many high-incidence cancers, and they also pose a significant risk for peripheral neuropathy. This study investigated the factors influencing paclitaxel-induced peripheral neuropathy (PIPN). We utilized PRO-CTCAE to assess the incidence of PIPN in patients receiving a tri-weekly regimen of single-agent albumin-bound paclitaxel through an online platform within one week after chemotherapy. Multivariable logistic regression was employed to analyze the impact of personal characteristics, clinical data and chemotherapy dose. All the statistical analyses were conducted in R studio. The incidence of acute severe to very severe PIPN was 36.7%, and the risk factors included per 200 mg increment in cumulative dose (OR 1.13, 95% 1.03 ∼ 1.24), estimated glomerular filtration rate < 90 ml/min/1.73m2 (OR 1.72, 95%CI 1.11 ∼ 2.66), anemia (OR 2.60, 95%CI 1.63 ∼ 4.15), albumin ≥ 40g/L (OR 1.74, 95%CI 1.04 ∼ 2.90), female (OR 1.98, 95%CI 1.19 ∼ 3.29), and overweight (OR 1.74, 95%CI 1.04 ∼ 2.91). The incidence of acute severe to very severe peripheral neuropathy caused by albumin-bound paclitaxel is relatively high. Nutritional status, gender, renal function and cumulative dose were all closely related to this incidence rate. Therefore, in the future, it is of great importance that a comprehensive and systematic assessment regarding the individual risks for patients be carried out in a meticulous manner. Relevant research should be conducted into the mechanisms underlying peripheral neuropathy, with particular attention to the role of individual factors.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"572-579"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postmarket review of photosensitivity associated with select BRAF and MEK inhibitors. 与BRAF和MEK抑制剂相关的光敏性上市后评价。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-08-01 DOI: 10.1080/1120009X.2025.2539565

Nicholas Chow, Melissa Reyes, Afrouz Nayernama, Graça M Dores, Ida-Lina Diak

引用次数: 0

Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis. 瑞非尼治疗复发性胶质母细胞瘤：单臂荟萃分析

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-10-01 Epub Date: 2025-11-20 DOI: 10.1080/1120009X.2025.2591474

Marcos Henrique da Silva Mezzari, Natan Lucca Lima, Bárbara Ghizoni Maggi, Davi Orli Machado Grüdtner, João Cândido Spezia de Souza, Luis Henrique Correa de Lara, Gustavo Rassier Isolan

{"title":"Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis.","authors":"Marcos Henrique da Silva Mezzari, Natan Lucca Lima, Bárbara Ghizoni Maggi, Davi Orli Machado Grüdtner, João Cândido Spezia de Souza, Luis Henrique Correa de Lara, Gustavo Rassier Isolan","doi":"10.1080/1120009X.2025.2591474","DOIUrl":"10.1080/1120009X.2025.2591474","url":null,"abstract":"Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"515-526"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0